Palforzia.pptx (39.64 kB)
Download file

Peanut (Arachis hypogaea) allergen powder-dnfp (Palforzia™) in peanut allergy: a profile of its use

Download (39.64 kB)
online resource
posted on 12.10.2021, 21:41 by Young-A Heo

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and conflict of interest Young-A Heo, a salaried employee of Adis International Ltd/Springer Nature and an editor of Drugs & Therapy Perspectives, was not involved in any publishing decisions for the manuscript and declares no declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.


Additional information about this Adis Drug Review can be found here.


Abstract

Peanut (Arachis hypogaea) allergen powder-dnfp (Palforzia; hereafter referred to as PTAH), is the first oral immunotherapy approved in the USA and European Commission for mitigating allergic reactions in children aged 4–17 years with peanut allergy. In the pivotal phase 3 studies in patients with peanut allergy, relative to placebo, PTAH significantly desensitized to peanut protein and reduced severity of allergic reactions to accidental peanut exposure, together with improvements in food allergy-related quality of life. The clinical benefits of PTAH were maintained with continued treatment for up to 2 years. Most adverse events with PTAH, including systemic allergic reactions, were of mild to moderate severity. Frequency and severity of adverse events decreased with continued treatment.


© Springer Nature Switzerland AG 2021





History